{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:59:06Z","timestamp":1787839146688,"version":"build-2784847793"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T00:00:00Z","timestamp":1510012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA03889"],"award-info":[{"award-number":["R01DA03889"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["T32 DA07209"],"award-info":[{"award-number":["T32 DA07209"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA006973"],"award-info":[{"award-number":["P30CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001079"],"award-info":[{"award-number":["UL1TR001079"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10OD020091"],"award-info":[{"award-number":["S10OD020091"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s00213-017-4769-4","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T02:13:22Z","timestamp":1510020802000},"page":"521-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences"],"prefix":"10.1007","volume":"235","author":[{"given":"Theresa M.","family":"Carbonaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Hurwitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland R.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,7]]},"reference":[{"issue":"2 Suppl","key":"4769_CR1","doi-asserted-by":"publisher","first-page":"16S","DOI":"10.1016\/S0893-133X(98)00135-3","volume":"21","author":"GK Aghajanian","year":"1999","unstructured":"Aghajanian GK, Marek GJ (1999) Serotonin and hallucinogens. Neuropsychopharmacology 21(2 Suppl):16S\u201323S","journal-title":"Neuropsychopharmacology"},{"key":"4769_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1196\/annals.1432.003","volume":"1139","author":"JA Banken","year":"2008","unstructured":"Banken JA, Foster H (2008) Dextromethorphan. Ann N Y Acad Sci 1139:402\u2013411","journal-title":"Ann N Y Acad Sci"},{"key":"4769_CR3","doi-asserted-by":"publisher","unstructured":"Barrett FS, Griffiths RR (2017) Classic hallucinogens and mystical experiences: phenomenology and neural correlates. Curr Top Behav Neurosci. https:\/\/doi.org\/10.1007\/7854_2017_474","DOI":"10.1007\/7854_2017_474"},{"issue":"11","key":"4769_CR4","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1177\/0269881115609019","volume":"29","author":"FS Barrett","year":"2015","unstructured":"Barrett FS, Johnson MW, Griffiths RR (2015) Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol 29(11):1182\u20131190","journal-title":"J Psychopharmacol"},{"issue":"12","key":"4769_CR5","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1177\/0269881116678781","volume":"30","author":"FS Barrett","year":"2016","unstructured":"Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffiths RR (2016) The challenging experience questionnaire: characterization of challenging experiences with psilocybin mushrooms. J Psychopharmacol 30(12):1279\u20131295","journal-title":"J Psychopharmacol"},{"key":"4769_CR6","doi-asserted-by":"crossref","unstructured":"Barrett FS, Robbins H, Smooke D, Brown JL, Griffiths RR (2017). Qualitative and quantitative features of music reported to support peak mystical experiences during psychedelic therapy sessions. Front Psychol 8:1238","DOI":"10.3389\/fpsyg.2017.01238"},{"key":"4769_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/jmt\/9.2.64","volume":"IX","author":"HL Bonny","year":"1972","unstructured":"Bonny HL, Pahnke WN (1972) The use of music in psychedelic (LSD) psychotherapy. J Music Therapy IX:64\u201387","journal-title":"J Music Therapy"},{"key":"4769_CR8","doi-asserted-by":"publisher","unstructured":"Brown RT, Nicholas CR, Cozzi NV, Gassman MC, Cooper KM, Muller D, Thomas CD, Hetzel SJ, Henriquez KM, Ribaudo AS, Hutson PR (2017) Pharmacokinetics of escalating doses of oral psilocybin in healthy adults. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-017-0540-6","DOI":"10.1007\/s40262-017-0540-6"},{"issue":"1","key":"4769_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00213-014-3658-3","volume":"232","author":"TM Carbonaro","year":"2015","unstructured":"Carbonaro TM, Eshleman AJ, Forster MJ, Cheng K, Rice KC, Gatch MB (2015) The role of 5-HT2A, 5-HT 2C and mGlu2 receptors in the behavioral effects of tryptamine hallucinogens N,N-dimethyltryptamine and N,N-diisopropyltryptamine in rats and mice. Psychopharmacology 232(1):275\u2013284","journal-title":"Psychopharmacology"},{"issue":"11","key":"4769_CR10","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1038\/sj.npp.1301146","volume":"31","author":"LP Carter","year":"2006","unstructured":"Carter LP, Richards BD, Mintzer MZ, Griffiths RR (2006) Relative abuse liability of GHB in humans: a comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB. Neuropsychopharmacology 31(11):2537\u20132551","journal-title":"Neuropsychopharmacology"},{"key":"4769_CR11","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.neuropharm.2012.01.010","volume":"62","author":"HK Delille","year":"2012","unstructured":"Delille HK, Becker JM, Burkhardt S, Bleher B, Terstappen GC, Schmidt M, Meyer AH, Unger L, Marek GJ, Mezler M (2012) Heterocomplex formation of 5-HT2A-mGlu2 and its relevance for cellular signaling cascades. Neuropharmacology 62:2184\u20132191","journal-title":"Neuropharmacology"},{"issue":"Suppl 2","key":"4769_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1055\/s-2007-979351","volume":"31","author":"A Dittrich","year":"1998","unstructured":"Dittrich A (1998) The standardized psychometric assessment of altered states of conciousness (ACSs) in humans. Pharmacopsychiatry 31(Suppl 2):80\u201384","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"4769_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bcp.2007.07.018","volume":"75","author":"WE Fantegrossi","year":"2008","unstructured":"Fantegrossi WE, Murnane KS, Reissig CJ (2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75(1):17\u201333","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"4769_CR14","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2011.09.055","volume":"147","author":"M Fribourg","year":"2011","unstructured":"Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahajan R, Park G, Adnewy SK, Hatcher C, Eltit JM, Ruta JD, Albizu L, Li Z, Umali A, Shim J, Fabiato A, MacKerell AD Jr, Brezina V, Sealfron SC, Filizola M, Gonzalez-Maeso J, Logothetis DE (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147(5):1011\u20131023","journal-title":"Cell"},{"key":"4769_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.neuron.2007.01.008","volume":"53","author":"J Gonzalez-Maeso","year":"2007","unstructured":"Gonzalez-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, Lira A, Bradley-Moore M, Ge Y, Zhou Q, Sealfon SC, Gingrich JA (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptormediated signaling pathways to affect behavior. Neuron 53:439\u2013452","journal-title":"Neuron"},{"key":"4769_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature06612","volume":"452","author":"J Gonzalez-Maeso","year":"2008","unstructured":"Gonzalez-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, Lopez-Gimenez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin\/glutamate receptor complex implicated in psychosis. Nature 452:93\u201397","journal-title":"Nature"},{"key":"4769_CR17","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1055\/s-2005-916185","volume":"38","author":"E Gouzoulis-Mayfrank","year":"2005","unstructured":"Gouzoulis-Mayfrank E, Heekeren K, Neukirch A, Stoll M, Stock C, Obradovic M, Kovar K-A (2005) Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): a double blind, cross-over study in healthy volunteers. Pharmacopsychiatry 38:301\u2013311","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"4769_CR18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187(3):268\u2013283 discussion 284-92","journal-title":"Psychopharmacology"},{"issue":"4","key":"4769_CR19","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s00213-011-2358-5","volume":"218","author":"RR Griffiths","year":"2011","unstructured":"Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology 218(4):649\u2013665","journal-title":"Psychopharmacology"},{"issue":"3","key":"4769_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0031-6865(97)00014-9","volume":"72","author":"F Hasler","year":"1997","unstructured":"Hasler F, Bourquin D, Brenneisen R, Bar T, Vollenweider FX (1997) Determinaton of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmokinetic profiles of oral and intravenous psilocybin in man. Pharm Acta Helv 72(3):175\u2013184","journal-title":"Pharm Acta Helv"},{"issue":"2","key":"4769_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00213-003-1640-6","volume":"172","author":"F Hasler","year":"2004","unstructured":"Hasler F, Grimberg U, Benz MA, Huber T, Vollenweider FX (2004) Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study. Psychopharmacology 172(2):145\u2013156","journal-title":"Psychopharmacology"},{"key":"4769_CR22","volume-title":"The psychology of religion: an empirical approach","author":"RW Hood","year":"2009","unstructured":"Hood RW, Hill PC, Bernard S (2009) The psychology of religion: an empirical approach. Guilford Press, New York"},{"key":"4769_CR23","volume-title":"Ketamine: dreams and realities","author":"KLR Jansen","year":"2004","unstructured":"Jansen KLR (2004) Ketamine: dreams and realities. Multidisciplinary Association for Psychedelic Studies (MAPS), Sarasota, FL"},{"issue":"6","key":"4769_CR24","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards WA, Griffiths RR (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22(6):603\u2013620","journal-title":"J Psychopharmacol"},{"issue":"19","key":"4769_CR25","doi-asserted-by":"publisher","first-page":"3607","DOI":"10.1007\/s00213-015-4014-y","volume":"232","author":"M Kaelen","year":"2015","unstructured":"Kaelen M, Barrett FS, Roseman L, Lorenz R, Family N, Bolstridge M, Carhart-Harris RL (2015) LSD enhances the emotional response to music. Psychopharmacology 232(19):3607\u20133614","journal-title":"Psychopharmacology"},{"issue":"4","key":"4769_CR26","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1111\/j.1468-5906.2012.01685.x","volume":"51","author":"KA MacLean","year":"2012","unstructured":"MacLean KA, Leoutsakos JM, Johnson MW, Griffiths RR (2012) Factor analysis of the mystical experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study Relig 51(4):721\u2013737","journal-title":"J Sci Study Relig"},{"key":"4769_CR27","unstructured":"MacLean KA, Johnson MW, Griffiths RR (2015) Hallucinogens and club drugs. In: Galanter M, Kleber HD, Bradu L (eds) The American Psychiatric Press Textbook of Substance Abuse Treatment, Fifth ed. The American Psychiatric Press, Arlington, VA, pp 209\u2013222"},{"key":"4769_CR28","first-page":"3","volume":"5","author":"R Metzner","year":"1965","unstructured":"Metzner R, Litwin G, Weil G (1965) The relation of expectation and mood to psilocybin reactions: a questionnaire study. Psychedelic Review 5:3\u201339","journal-title":"Psychedelic Review"},{"key":"4769_CR29","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neulet.2011.01.046","volume":"493","author":"JL Moreno","year":"2011","unstructured":"Moreno JL, Holloway T, Albizu L, Sealfon SC, Gonz\u00e1lez-Maeso J (2011) Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci Lett 493:76\u201379","journal-title":"Neurosci Lett"},{"issue":"5","key":"4769_CR30","first-page":"358","volume":"7","author":"H Morris","year":"2014","unstructured":"Morris H, Wallach J (2014) From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. Drug Test Anal 7(5):358\u2013367","journal-title":"Drug Test Anal"},{"issue":"2","key":"4769_CR31","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0022-3565(25)24438-X","volume":"272","author":"GK Mumford","year":"1995","unstructured":"Mumford GK, Rush CR, Griffiths RR (1995) Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272(2):570\u2013580","journal-title":"J Pharmacol Exp Ther"},{"key":"4769_CR32","volume-title":"The cosmic serpent DNA and the origins of knowledge","author":"J Narby","year":"1999","unstructured":"Narby J (1999) The cosmic serpent DNA and the origins of knowledge. Jeremy P. Tarcher\/Putnam, New York, NY"},{"key":"4769_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.016","volume":"159","author":"L Nguyen","year":"2016","unstructured":"Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR (2016) Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther 159:1\u201322","journal-title":"Pharmacol Ther"},{"key":"4769_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355","journal-title":"Pharmacol Rev"},{"issue":"4","key":"4769_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1080\/1355621021000005937","volume":"7","author":"T Passie","year":"2002","unstructured":"Passie T, Seifert J, Schneider U, Emrich HM (2002) The pharmacology of psilocybin. Addict Biol 7(4):357\u2013364","journal-title":"Addict Biol"},{"key":"4769_CR36","doi-asserted-by":"publisher","unstructured":"Preller KH, Vollenweider FX (2016) Phenomenology, structure, and dynamic of psychedelic states. Curr Top Behav Neurosci. https:\/\/doi.org\/10.1007\/7854_2016_459","DOI":"10.1007\/7854_2016_459"},{"issue":"1","key":"4769_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00213-012-2680-6","volume":"223","author":"CJ Reissig","year":"2012","unstructured":"Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR (2012) High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology 223(1):1\u201315","journal-title":"Psychopharmacology"},{"key":"4769_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","volume":"26","author":"A Rickli","year":"2016","unstructured":"Rickli A, Moning OD, Hoener MC, Liechti ME (2016) Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. Eur Neuropsychopharmacol 26:1327\u20131337","journal-title":"Eur Neuropsychopharmacol"},{"key":"4769_CR39","volume-title":"2014 National Survey on Drug Use and Health: detailed tables. Center for Behavioral Health Statistics and Quality","author":"SAMHSA","year":"2015","unstructured":"SAMHSA (2015) 2014 National Survey on Drug Use and Health: detailed tables. Center for Behavioral Health Statistics and Quality. Substance Abuse and Mental Health Services Administration Rockville, MD"},{"key":"4769_CR40","volume-title":"2015 National Survey on Drug Use and Health: detailed tables. Center for Behavioral Health Statistics and Quality","author":"SAMHSA","year":"2016","unstructured":"SAMHSA (2016) 2015 National Survey on Drug Use and Health: detailed tables. Center for Behavioral Health Statistics and Quality. Substance Abuse and Mental Health Services Administration Rockville, MD"},{"key":"4769_CR41","doi-asserted-by":"publisher","first-page":"46421","DOI":"10.1038\/srep46421","volume":"7","author":"MM Schartner","year":"2017","unstructured":"Schartner MM, Carhart-Harris RL, Barrett AB, Seth AK, Muthukumaraswamy SD (2017) Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. Sci Rep 7:46421","journal-title":"Sci Rep"},{"issue":"6","key":"4769_CR42","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/clpt.1985.235","volume":"38","author":"B Schmid","year":"1985","unstructured":"Schmid B, Bircher J, Preisig R, Kupfer A (1985) Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38(6):618\u2013624","journal-title":"Clin Pharmacol Ther"},{"key":"4769_CR43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00213-012-2811-0","volume":"225","author":"A Schmidt","year":"2013","unstructured":"Schmidt A, Kometer M, Bachmann R, Seifritz E, Vollenweider F (2013) The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions. Psychopharmacol 225:227\u2013239","journal-title":"Psychopharmacol"},{"key":"4769_CR44","volume-title":"TiHKAL","author":"A Shulgin","year":"1997","unstructured":"Shulgin A, Shulgin A (1997) TiHKAL. Transform Press, Berkeley, CA"},{"key":"4769_CR45","volume-title":"DMT: the spirit molecule","author":"R Strassman","year":"2001","unstructured":"Strassman R (2001) DMT: the spirit molecule. Park Street Press, Rochester, VA"},{"key":"4769_CR46","doi-asserted-by":"crossref","unstructured":"Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98\u2013108","DOI":"10.1001\/archpsyc.1994.03950020022002"},{"issue":"8","key":"4769_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012412","volume":"5","author":"E Studerus","year":"2010","unstructured":"Studerus E, Gamma A, Vollenweider FX (2010) Psychometric evaluation of the altered states of consciousness rating scale (OAV). PLoS One 5(8):e12412","journal-title":"PLoS One"},{"key":"4769_CR48","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","volume":"164","author":"CP Taylor","year":"2016","unstructured":"Taylor CP, Traynelis SF, Siffert J, Pope LE, Matsumoto RR (2016) Pharmacology of dextromethorphan: relevance to dextromethorphan\/quinidine (nuedexta(R)) clinical use. Pharmacol Ther 164:170\u2013182","journal-title":"Pharmacol Ther"},{"issue":"3","key":"4769_CR49","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.euroneuro.2013.12.006","volume":"24","author":"F Tyls","year":"2014","unstructured":"Tyls F, Palenicek T, Horacek J (2014) Psilocybin\u2014summary of knowledge and new perspectives. Eur Neuropsychopharmacol 24(3):342\u2013356","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"4769_CR50","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0731-7085(02)00134-6","volume":"30","author":"SS Vengurlekar","year":"2002","unstructured":"Vengurlekar SS, Heitkamp J, McCush F, Velagaleti PR, Brisson JH, Bramer SL (2002) J Pharm Biomed Anal 30(1):113\u2013124","journal-title":"J Pharm Biomed Anal"},{"issue":"9","key":"4769_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nrn2884","volume":"11","author":"FX Vollenweider","year":"2010","unstructured":"Vollenweider FX, Kometer M (2010) The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat Rev Neurosci 11(9):642\u2013651","journal-title":"Nat Rev Neurosci"},{"issue":"17","key":"4769_CR52","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","volume":"9","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Babler A, Vogel H, Hell D (1998) Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport 9(17):3897\u20133902","journal-title":"Neuroreport"},{"key":"4769_CR53","unstructured":"White W (2002) The DXM experience. https:\/\/www.erowid.org\/chemicals\/dxm\/faq\/dxm_experience.shtml#toc.5 . Accessed 15 July 2017"},{"key":"4769_CR54","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00213-008-1356-8","volume":"203","author":"JC Winter","year":"2009","unstructured":"Winter JC (2009) Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology 203:251\u2013263","journal-title":"Psychopharmacology"},{"key":"4769_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00213-003-1636-2","volume":"172","author":"JC Winter","year":"2004","unstructured":"Winter JC, Eckler JR, Rabin RA (2004) Serotonergic\/glutamatergic interactions: the effects of mGlu2\/3 receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology 172:233\u2013240","journal-title":"Psychopharmacology"},{"key":"4769_CR56","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1037\/1528-3542.8.4.494","volume":"8","author":"M Zentner","year":"2008","unstructured":"Zentner M, Grandjean D, Scherer KR (2008) Emotions evoked by the sound of music: characterization, classification, and measurement. Emotion 8:494\u2013521","journal-title":"Emotion"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-017-4769-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-017-4769-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T18:10:45Z","timestamp":1750961445000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-017-4769-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,7]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["4769"],"URL":"https:\/\/doi.org\/10.1007\/s00213-017-4769-4","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,7]]},"assertion":[{"value":"17 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Board of the Johns Hopkins University School of Medicine. Participants gave their written informed consent before beginning the study procedures and were paid for their participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Carbonaro is an employee of the U.S. Food and Drug Administration (FDA); however, the views presented in this article do not necessarily reflect those of the FDA and no official support or endorsement of this article by the FDA is intended or should be inferred. Roland Griffiths is on the Board of Directors of the Heffter Research Institute.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}